Company: AZN
Filing Date: 2025-10-20
Form Type: 6-K
Source: 0001654954-25-011951
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-10-20
Form: 6-K
Chunk 7
---
 of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). Available at: https://clinicaltrials.gov/ct2/show/NCT04851964 . Accessed October 2025.

21. Zhang M, et al. Hypoxia induces the production of epithelial-derived cytokines in eosinophilic chronic rhinosinusitis with nasal polyps. Int Immunopharmacol. 2023;121:110559.

22. AstraZeneca Data on file. 2025. REF-278452.

23. Clinicaltrials.gov. Tezepelumab COPD Exacerbation Study (COURSE) [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT04039113 . Accessed October 2025.

24. Clinicaltrials.gov. Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING). Available at: https://clinicaltrials.gov/study/NCT05583227 . Accessed October 2025.

25. AstraZeneca news release. Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html . Accessed October 2025.

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:20 October 2025

| By: /s/           
 Matthew Bowden    |
| Name:             
 Matthew Bowden    |
| Title:            
 Company Secretary |